Theravance Biopharma (TBPH) Operating Income Growth (1y) (2014 - 2026)
Theravance Biopharma (TBPH) Operating Income Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 1,386.07% |
| 10 | Theravance Biopharma | 866.36 Mn | 471.69 Mn | - | 34.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.30% |
| Dec 31, 2025 | 317.52% |
| Sep 30, 2025 | 40.44% |
| Jun 30, 2025 | 82.65% |
| Mar 31, 2025 | -28.79% |
| Dec 31, 2024 | -47.44% |
| Sep 30, 2024 | -23.71% |
| Jun 30, 2024 | 2.59% |
| Mar 31, 2024 | 55.01% |
| Dec 31, 2023 | 64.20% |
| Sep 30, 2023 | 4.20% |
| Jun 30, 2023 | 40.02% |
| Mar 31, 2023 | 35.30% |
| Dec 31, 2022 | 68.96% |
| Sep 30, 2022 | 82.95% |
| Jun 30, 2022 | 58.07% |
| Mar 31, 2022 | 54.11% |
| Dec 31, 2021 | 26.57% |
| Sep 30, 2021 | 30.02% |
| Jun 30, 2021 | 11.18% |